RxDoctor Payments DataLook up a doctor →

Henry Rhee, MD

Infectious Disease · Centreville, VANPI 1265489868

Payments from drug & device makers

$15,275in general payments, 2019–2025

Across 728 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$3K
  • Gilead$2K
  • AbbVie$2K
  • Merck$1K
  • Melinta Therapeutics, LLC$1K
  • Theratechnologies Inc.$895
  • plus $5K from 17 others

What the payments were for

  • Speaking & faculty fees$4053%
  • Food & beverage$14,16693%
  • Education$7045%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,275 in reported general payments places this provider in the 85th percentile of 194 infectious disease providers in Virginia.

See all infectious disease providers in Virginia

Medicare billing

Part B allowed, 2024
$83,564
Medicare patients
245
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala34$138,156
RukobiaFostemsavir Tromethamine12$108,669
Daptomycin110$52,446
JulucaDolutegravir/Rilpivirine13$45,759
DovatoDolutegravir Sodium/Lamivudine13$38,996
TeflaroCeftaroline Fosamil Acetate11$34,243
ErtapenemErtapenem Sodium54$26,557
Tigecycline13$19,625
Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium43$13,236
MicafunginMicafungin Sodium20$7,155
Meropenem80$7,098
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam19$3,373
CeftriaxoneCeftriaxone Sodium30$2,790
Methenamine Hippurate19$2,484
Vancomycin Hcl18$2,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyRukobia, Juluca, Dovato$2,760$193,42438 claims
GileadBiktarvy$2,401$138,15634 claims
AbbVieTeflaro$2,029$34,24311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 194 infectious disease providers in Virginia.

Other infectious disease in Centreville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →